Zobrazeno 71 - 80
of 130
pro vyhledávání: '"Romain Guieze"'
Autor:
Marie Sebert, Hervé Dombret, Norbert Vey, Sylvie Chevret, Mathilde Hunault, Lionel Ades, Pierre Fenaux, Aspasia Stamatoullas, Emmanuel Raffoux, Andrea Toma, Romain Guieze, Laure Stalnikiewicz, Christian Recher, Eric Wattel, Cendrine Chaffaut, Claude Gardin, Thomas Prebet, Krimo Bouabdallah
Publikováno v:
Haematologica
Haematologica, 2017, 102 (4), pp.728-735. ⟨10.3324/haematol.2016.151894⟩
Haematologica, Ferrata Storti Foundation, 2017, 102 (4), pp.728-735. ⟨10.3324/haematol.2016.151894⟩
Haematologica, 2017, 102 (4), pp.728-735. ⟨10.3324/haematol.2016.151894⟩
Haematologica, Ferrata Storti Foundation, 2017, 102 (4), pp.728-735. ⟨10.3324/haematol.2016.151894⟩
Patients with acute myeloblastic leukemia or higher risk myelodysplastic syndromes with 5q deletion (generally within a complex karyotype) respond poorly to intensive chemotherapy and have very poor survival. In this population, we evaluated escalati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eda6ab6c6c188dd0a0ee5a1628d4bb9e
https://hal.science/hal-01655899
https://hal.science/hal-01655899
Autor:
Daniel Orbach, Marie Wislez, Jacques-Olivier Bay, Juliette Thariat, Stéphane Vignot, Anthony Gonçalves, Romain Guieze, Nicolas Magné, Nicolas Penel, Thierry André
Publikováno v:
Bulletin du Cancer
Bulletin du Cancer, John Libbey Eurotext, 2017, 104 (1), pp.6-19. ⟨10.1016/j.bulcan.2016.11.009⟩
Bulletin du Cancer, 2017, 104 (1), pp.6-19. ⟨10.1016/j.bulcan.2016.11.009⟩
Bulletin du Cancer, John Libbey Eurotext, 2017, 104 (1), pp.6-19. 〈10.1016/j.bulcan.2016.11.009〉
Bulletin du Cancer, John Libbey Eurotext, 2017, 104 (1), pp.6-19. ⟨10.1016/j.bulcan.2016.11.009⟩
Bulletin du Cancer, 2017, 104 (1), pp.6-19. ⟨10.1016/j.bulcan.2016.11.009⟩
Bulletin du Cancer, John Libbey Eurotext, 2017, 104 (1), pp.6-19. 〈10.1016/j.bulcan.2016.11.009〉
Among the results presented at international congresses or published in scientific journals, which are those that have a real impact on daily practice? Every year, the editorial board of the Bulletin du Cancer proposes a selection of key data in onco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cc4dcc85745938a4997c1a19147238b
https://hal.archives-ouvertes.fr/hal-01655990
https://hal.archives-ouvertes.fr/hal-01655990
Autor:
Jacques Delaunay, Romain Guieze, Jacques-Olivier Bay, Richard Lemal, Cécile Moluçon-Chabrot, Thibault Brotelle
Publikováno v:
Bulletin du Cancer. 101:211-218
Gemtuzumab ozogamicin (GO) is a humanized monoclonal antibody anti-CD33 conjugated with calicheamicin and was indicated for acute myeloid leukemia (AML) patients. It was initially approved in 2000 by FDA thank to promising results from a phase II tri
Autor:
B. Branco, Aline Clavert, Lucie Oberic, A. Teste, Loic Ysebaert, A. Calleja, Kamel Laribi, Romain Guieze, F. Bijou, Anne Sophie Michallet, Annie Brion
Publikováno v:
Hematological Oncology. 37:384-384
Autor:
Richard Lemal, Marie Robin, Aurélie Ravinet, Romain Guieze, Jacques-Olivier Bay, Victoria Cacheux
Publikováno v:
Bulletin du Cancer. 100:897-902
Ruxolitinib is a JAK/STAT inhibitor, which has demonstrated clinical benefits in patients with intermediate-2 and high-risk myelofibrosis. Moreover, first results of recent clinical trials show a trend to better overall survival with ruxolitinib, whi
Autor:
Vamsi K. Mootha, John G. Doench, Shuqiang Li, Alexis Jourdain, Aina Zurita Martinez, Giulia Notarangelo, Matthew S. Davids, Cory M. Johannessen, María Hernández-Sánchez, Romain Guieze, Philip A. Thompson, Zacchary Cartun, Kaitlyn Baranowski, Ozan Aygün, Sun Jing, Wade Harper, Catherine J. Wu, Donna Neuberg, Heo Jin-Mi, Steven A. Carr, Ignaty Leshchiner, Federica Piccioni, Daniel Rosebrock, Vivian M. Liu, Jennifer R. Brown, Dimitri Livitz, Christopher J. Ott, Gad Getz, William G. Wierda, Anthony Letai
Publikováno v:
Blood. 132:893-893
The FDA-approval of potent targeted therapies has led to great changes in the therapeutic landscape of chronic lymphocytic leukemia (CLL). As a key example, venetoclax, a first-in-class BCL-2 inhibitor, leads to response in about 80% of patients with
Autor:
Claire Quiney, Caroline Dartigeas, Lauren Veronese, Frederic Davi, Loic Ysebaert, Patricia Combes, Brigitte Dreyfus, Laurence Sanhes, Magali Le Garff-Tavernier, Pauline Robbe, Emmanuelle Ferrant, Roselyne Delepine, Anna Schuh, Hélène Merle-Béral, Bruno Pereira, Choquet Sylvain, Pierre Feugier, Florence Nguyen-Khac, Jacques-Olivier Bay, Beatrice Mahe, Olivier Tournilhac, Stéphane Leprêtre, Thérèse Aurran, Alain Delmer, Malgorzata Truchan-Graczyk, Veronique Leblond, Marie-Sarah Dilhuydy, Gian Matteo Pica, Romain Guieze, Sophie de Guibert
Publikováno v:
Blood. 132:3127-3127
Introduction: The 17p deletion (del(17p)) resulting in loss of the TP53 gene is associated with impaired response to genotoxic agents and has an impact on PFS following BTK inhibitor and possibly also venetoclax. The del(17p) usually coincides with T
Autor:
Pierre Morel, Laure Farnault, Thérèse Aurran, Caroline Dartigeas, Sandy Amorim, Alain Delmer, Isabelle Plantier, Florian Bouclet, Loic Ysebaert, Sophie de Guibert, Olivier Tournilhac, Charles Herbaux, Bénédicte Hivert, Anaise Blouet, Marie-Sarah Dilhuydy, Romain Guieze, Emmanuelle Tchernonog, Anne Calleja, Jacques-Olivier Bay, Anne Lavaud, Florence Cymbalista, Damien Roos-Weil, Anne-Sophie Michallet, Natalia Dmytruk, Kamel Laribi, Pierre Feugier, Jehan Dupuis
Publikováno v:
Blood. 132:5549-5549
Introduction.The BCL-2 inhibitor venetoclax has demonstrated high efficiency in relapsed/refractory (R/R) CLL patients with an overall response rate (ORR) of 79%, regardless of the TP53gene status. Venetoclax has then been EMEA-approved for CLL patie
Autor:
Xavier Poiré, Richard Lemal, Aurélie Ravinet, Olivier Tournilhac, Jacques-Olivier Bay, Jean-Henri Bourhis, Marc Bernard, Patrice Ceballos, Laura Bounaix, Eric Hermet, Romain Guieze, Johan Maertens, Patrice Chevallier, Hélène Labussière-Wallet, Natacha Maillard, David Michonneau, Thierry de Revel, Stéphanie Nguyen, Lionel Mannone, Didier Blaise, Ibrahim Yakoub-Agha
Publikováno v:
Blood. 132:3457-3457
Introduction. Chronic lymphocytic leukemia (CLL) has typically an indolent course but can undergo transformation into a more aggressive lymphoma (mainly of diffuse large B-cell lymphoma histology) that is called Richter's syndrome. While the advent o
Autor:
Pierre Verrelle, Eric Hermet, Aurélie Ravinet, Romain Guieze, Sébastien Bailly, Julian Biau, Richard Lemal, Jacques-Olivier Bay, Cécile Moluçon-Chabrot, Régis Peffault de Latour, Olivier Tournilhac, Aliénor Xhaard
Publikováno v:
Bulletin du Cancer. 100:587-599
Hematology Oncology has a rich history including few crucial therapeutic innovations. These were possible because of the evolution of the cell and molecular biology allowing a better understanding of basic mechanisms of cancerogenesis. We propose her